Bang yj et al. lancet 2010 376: 687-697
웹Methods/Design: This single-center study was designed to combine low-dose apatinib with camrelizumab plus the SOX regimen in diagnosed potentially resectable and initially unresectable AGC/GEJC. This a prospective, open-label, single-arm, dose escalation and extension phase Ib clinical trial, conducted in Jiangsu Province Hospital, beginning ... 웹2014년 12월 16일 · Bang YJ et al. The Lancet 2010;376(9742):687-697. 11 3 TOGA - Overall survival in patients with Her2-positive tumours (IHC2+/FISH+ or IHC3+) 1.0 0.8 0.6 0.4 0.2 0.0 ... Redrawn from Bang YJ et al. The Lancet 2010;376(9742):687-697. Metastatic gastric cancer: Results with targeted therapies (1st line)
Bang yj et al. lancet 2010 376: 687-697
Did you know?
웹2016년 5월 3일 · Bang YJ ; Van Cutsem E ; Feyereislova A ; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697. 웹2024년 5월 29일 · Editorial Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. …
웹2024년 9월 25일 · Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (4937) Google Scholar; ... Bang YJ ; Lordick F ; et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. 웹2024년 3월 23일 · Bang YJ ; Van Cutsem E ; Feyereislova A ; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer ... Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (5240) Google Scholar;
웹2013년 10월 24일 · Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010;376(9742):687-697. 웹Lancet. 2010;376(9742):687–97. CrossRefPubMed Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. CrossRef PubMed
웹2024년 6월 27일 · Bang YJ, Cutsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 ... Lancet. …
웹Lancet 376(9742):687–697 CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. greatest show on earth music웹Kelley JR and Duggan JM. J Clin Epidemiol 2003;56:1–9. Bang YJ, et al. Lancet 2010;376:687–697. Bang YJ, et al. J Clin Oncol 2008;26:Abstract 4526. Gravalos C and Jimeno A. Ann Oncol 2008;19:1523–1529. •HER2蛋白 • 分子量185 kDa的糖蛋白: flipping houses designer websites웹2일 전 · Bang YJ, Van Cutsem E, Feyereislova A, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment … greatest show on earth musical